Insulet (NASDAQ:PODD) Price Target Cut to $247.00 by Analysts at Leerink Partners

Insulet (NASDAQ:PODD) had its price target cut by investment analysts at Leerink Partners from $360.00 to $247.00 in a report issued on Thursday,MarketScreener reports. Leerink Partners’ price target suggests a potential upside of 56.85% from the stock’s current price.

A number of other research analysts also recently issued reports on the stock. Sanford C. Bernstein dropped their price target on shares of Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a research report on Thursday. Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 price objective (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Jefferies Financial Group lowered their target price on Insulet from $400.00 to $360.00 in a report on Thursday. Royal Bank Of Canada restated an “outperform” rating and set a $325.00 price target on shares of Insulet in a report on Tuesday, April 14th. Finally, Stifel Nicolaus lowered their price objective on shares of Insulet from $370.00 to $350.00 and set a “buy” rating for the company in a research note on Wednesday, February 4th. Eighteen analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $263.91.

Insulet Trading Up 4.1%

PODD traded up $6.20 during midday trading on Thursday, hitting $157.48. 81,593 shares of the company were exchanged, compared to its average volume of 1,069,567. The firm’s 50 day moving average price is $212.92 and its 200-day moving average price is $264.96. Insulet has a 1-year low of $148.30 and a 1-year high of $354.88. The firm has a market capitalization of $10.91 billion, a P/E ratio of 44.72, a P/E/G ratio of 0.99 and a beta of 1.20. The company has a quick ratio of 2.15, a current ratio of 2.81 and a debt-to-equity ratio of 0.61.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The company had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. During the same period last year, the company earned $1.02 earnings per share. The firm’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities analysts forecast that Insulet will post 6.27 EPS for the current fiscal year.

Insider Activity

In other Insulet news, Director Michael R. Minogue acquired 2,030 shares of Insulet stock in a transaction dated Wednesday, February 25th. The stock was purchased at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the acquisition, the director directly owned 17,483 shares of the company’s stock, valued at $4,304,839.09. This represents a 13.14% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.36% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Larson Financial Group LLC grew its holdings in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. bought a new stake in Insulet in the 4th quarter worth about $26,000. Elyxium Wealth LLC purchased a new stake in Insulet in the 4th quarter valued at about $28,000. DV Equities LLC bought a new position in shares of Insulet during the 4th quarter worth approximately $28,000. Finally, MV Capital Management Inc. bought a new position in shares of Insulet during the 4th quarter worth approximately $29,000.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Q1 results beat expectations — EPS $1.42 vs. ~$1.19 consensus and revenue $761.7M (+33.9% Y/Y), driven by strong Omnipod demand. This confirms solid top-line momentum. Insulet Reports First Quarter 2026 Results
• Positive Sentiment: Company raised its annual revenue growth outlook after the quarter, citing sustained demand for its tubeless insulin pumps — a supportive signal for medium-term sales trajectory. Insulet lifts annual revenue forecast after quarterly beat
• Neutral Sentiment: Earnings call commentary was broadly upbeat (Omnipod growth emphasized) and management provided slide materials/transcripts for investors to parse execution details. These materials clarify drivers but don’t change the headline beat. Q1 2026 Earnings Call Transcript
• Negative Sentiment: FY 2026 EPS guidance appears below some Street estimates (company set FY EPS around ~6.21 vs. ~6.33 consensus cited by analysts), which likely disappointed investors despite the revenue upgrade. Earnings and guidance details
• Negative Sentiment: BTIG cut its price target from $320 to $260 (still a Buy rating); the PT reduction signals some analyst re?valuation and may have amplified selling pressure. BTIG price target cut

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.